Full text is available at the source.
A meta‐analysis comparing clinical effects of short‐ or long‐acting GLP ‐1 receptor agonists versus insulin treatment from head‐to‐head studies in type 2 diabetic patients
Comparing short- and long-acting GLP-1 treatments with insulin in type 2 diabetes patients
AI simplified
Abstract
GLP-1 receptor agonists (RAs) reduced HbA1c by 0.12% more effectively than insulin in patients with type 2 diabetes.
- Basal insulin was more effective in lowering fasting plasma glucose by 1.8 mmol/L compared to GLP-1 RAs.
- GLP-1 RAs led to a significant weight reduction of 3.71 kg, whereas insulin did not.
- The occurrence of hypoglycaemic episodes was 34% lower in patients using GLP-1 RAs than those on insulin.
- Systolic blood pressure decreased and heart rate increased with GLP-1 RAs.
- GLP-1 RAs significantly lowered triglycerides and LDL cholesterol levels.
- Long-acting GLP-1 RAs were more effective than short-acting ones in reducing HbA1c and fasting glucose.
AI simplified